Lifeboat Foundation

In the last few years, most of the data such as books, videos, pictures, medical and even the genetic information of humans are moving toward digital formats. Laptops, tablets, smartphones and wearable devices are the major source of this digital data transformation and are becoming the core part of our daily life. As a result of this transformation, we are becoming the soft target of various types of cybercrimes. Digital forensic investigation provides the way to recover lost or purposefully deleted or hidden files from a suspect’s device. However, current man power and government resources are not enough to investigate the cybercrimes. Unfortunately, existing digital investigation procedures and practices require huge interaction with humans; as a result it slows down the process with the pace digital crimes are committed. Machine learning (ML) is the branch of science that has governs from the field of AI. This advance technology uses the explicit programming to depict the human-like behaviour. Machine learning combined with automation in digital investigation process at different stages of investigation has significant potential to aid digital investigators. This chapter aims at providing the research in machine learning-based digital forensic investigation, identifies the gaps, addresses the challenges and open issues in this field.

Robotmaker Boston Dynamics has finally put its four-legged robot Spot on general sale. After years of development, the company began leasing the machine to businesses last year, and, as of today, is now letting any US firm buy their very own Spot for $74,500.

It’s a hefty price tag, equal to the base price for a luxury Tesla Model S. But Boston Dynamics says, for that money, you’re getting the most advanced mobile robot in the world, able to go pretty much anywhere a human can (as long as there are no ladders involved).

Continue reading “Boston Dynamics will now sell any business its own Spot robot for $74,500” »

The cosmos contains a Higgs field—similar to an electric field—generated by Higgs bosons in the vacuum. Particles interact with the field to gain energy and, through Albert Einstein’s iconic equation, E=mc², mass. The Standard Model of particle physics, although successful at describing elementary particles and their interactions at low energies, does not include a viable and hotly debated dark-matter particle. The only possible candidates, neutrinos, do not have the right properties to explain the observed dark matter.

“One particularly interesting possibility is that these long-lived dark particles are coupled to the Higgs boson in some fashion—that the Higgs is actually a portal to the dark world. We know for sure there’s a dark world, and there’s more energy in it than there is in ours. It’s possible that the Higgs could actually decay into these long-lived particles,” said LianTao Wang, a University of Chicago physicist, in 2019, referring to the last holdout particle in physicists’ grand theory of how the universe works, discovered at the LHC in 2012, filling the last gap in the standard model of fundamental particles and forces. Since then, the standard model has stood up to every test, yielding no hints of new physics.

The dark world makes up more than 95 percent of the universe, but scientists only know it exists from its effects—” like a poltergeist you can only see when it pushes something off a shelf.” We know there’s dark matter because like the poltergeist, we can see gravity acting on it keeping galaxies from flying apart.

Dexamethasone, a cheap and widely used steroid, has become the first drug shown to be able to save lives among Covid-19 patients in what scientists hailed as a “major breakthrough”.

Results of trials announced on Tuesday showed dexamethasone, which is used to reduce inflammation in other diseases, reduced death rates by around a third among the most severely ill Covid-19 patients admitted to hospital.

The results suggest the drug should immediately become standard care in patients with severe cases of the pandemic disease, said the researchers who led the trials.

In 2017, Stanford University researchers presented a new device that mimics the brain’s efficient and low-energy neural learning process. It was an artificial version of a synapse — the gap across which neurotransmitters travel to communicate between neurons — made from organic materials. In 2019, the researchers assembled nine of their artificial synapses together in an array, showing that they could be simultaneously programmed to mimic the parallel operation of the brain.

Now, in a paper published June 15 in Nature Materials, they have tested the first biohybrid version of their artificial synapse and demonstrated that it can communicate with living cells. Future technologies stemming from this device could function by responding directly to chemical signals from the brain. The research was conducted in collaboration with researchers at Istituto Italiano di Tecnologia (Italian Institute of Technology – IIT) in Italy and at Eindhoven University of Technology (Netherlands).

“This paper really highlights the unique strength of the materials that we use in being able to interact with living matter,” said Alberto Salleo, professor of materials science and engineering at Stanford and co-senior author of the paper. “The cells are happy sitting on the soft polymer. But the compatibility goes deeper: These materials work with the same molecules neurons use naturally.”

The U.S. Food and Drug Administration has for the first time approved a video game for treating attention deficit hyperactivity disorder in children.

The FDA said Monday the game built by Boston-based Akili Interactive Labs can improve attention function.

The game, called EndeavorRx, requires a prescription and is designed for children ages 8 to 12 with certain symptoms of ADHD.

If only we had working longevity/aging reversal science now.

People under the age of 20 are half as likely to contract COVID-19 than the rest of the population, according to new modeling released on Tuesday that suggests four out of five infected young people show no symptoms.

The research, published in the Nature Medicine Journal, could help inform the next moves of governments under pressure to reopen schools and colleges shuttered since the start of the pandemic.

Continue reading “Under-20s half as likely to contract coronavirus: study” »

Researchers in England say they have the first evidence that a drug can improve COVID-19 survival: A cheap, widely available steroid reduced deaths by up to one third in severely ill hospitalized patients.

The results were announced Tuesday and the British government immediately authorized the drug’s use across the United Kingdom for coronavirus patients like those who did well in the study. Researchers said they would publish results soon, and several independent experts said it’s important to see details to know how much of a difference the drug, dexamethasone, might make and for whom.

But “bottom line is, good news,” said the United States’ top infectious disease expert, Dr. Anthony Fauci. “This is a significant improvement in the available therapeutic options that we have.”

A pair of researchers at University College London has found that people with low socioeconomic status experience more declines in age-related functions as they grow older than do people who have a higher socioeconomic status. In their paper published in Proceedings of the National Academy of Sciences, Andrew Steptoe and Paola Zaninotto describe their study of data from the English Longitudinal Study of Ageing, and what they learned.

Prior research has shown that poor people tend to suffer more adverse health effects than those who are better off. They also tend to die younger. But one area of aging that has not been well-studied is the impact of poverty on age-related functional decline, associated with such symptoms as loss of hearing or muscle strength. To learn more about the relationship between socioeconomic status and age-related functional decline, the researchers analyzed data in the English Longitudinal Study of Ageing—an ongoing long-term study of the aging process. Launched in 2002, the study involved collecting data on volunteers aged 50 and over as they grew older. The data includes both medical and physical information, along with test results designed to measure cognitive and emotional levels. The data sample for this new effort included information on 5,018 people 52 years of age or older as they aged over periods of six to eight years.

The researchers found that people living at the lower end of the economic spectrum performed worse on every measure of age-related functionality. Those less well-off lost grip strength, lung function, gait speed, processing speed and executive function. They also tended to report enjoying life less than those who were more affluent. The researchers noted their findings were independent of race, gender, education or age. They also found that those of lesser means experienced more vision problems and were more likely to be depressed.